Radiotherapy for Rhabdomyosarcoma: Indications and Outcome

Clinical Oncology

Volumn 25, Issue 1, 2013, Pages 27-35

  Terezakis, S A ^a   Wharam, M D ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

IMRT; Paediatric radiation; Paediatric tumours; Proton therapy; Rhabdomyosarcoma

Indexed keywords

CYCLOPHOSPHAMIDE; DACTINOMYCIN; VINCRISTINE;

ADD ON THERAPY; ARTICLE; BLADDER CANCER; BRACHYTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; DIAGNOSTIC IMAGING; DOSIMETRY; ENOPHTHALMOS; EXTERNAL BEAM RADIOTHERAPY; FAILURE FREE SURVIVAL; FOLLOW UP; HEAD AND NECK CANCER; HEPATOBILIARY SYSTEM TUMOR; HIGH RISK PATIENT; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LIMB TUMOR; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MORBIDITY; NUCLEAR MAGNETIC RESONANCE IMAGING; ORBIT CANCER; ORBIT DISEASE; ORBITAL HYPOPLASIA; OVERALL SURVIVAL; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROTON THERAPY; RADIATION DOSE ESCALATION; RADIATION DOSE FRACTIONATION; RETROPERITONEAL TUMOR; RHABDOMYOSARCOMA; SALVAGE THERAPY; TESTIS CANCER; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR VOLUME; UTERUS CANCER; VAGINA CANCER; VULVA CANCER;

HEAD AND NECK NEOPLASMS; HUMANS; PROGNOSIS; RADIOTHERAPY, INTENSITY-MODULATED; RHABDOMYOSARCOMA; TREATMENT OUTCOME;

EID: 84871432971     PISSN: 09366555     EISSN: 14332981     Source Type: Journal    
DOI: 10.1016/j.clon.2012.07.009     Document Type: Article

References (49)

1. Crist W.M., Anderson J.R., Meza J.L., et al. Intergroup Rhabdomyosarcoma Study-IV: Results for patients with nonmetastatic disease. J Clin Oncol 2001, 19(12):3091-3102.
2. Fredericks W.J., Galili N., Mukhopadhyay S., et al. The PAX3-FKHR fusion protein created by the t(2;13) translocation in alveolar rhabdomyosarcomas is a more potent transcriptional activator than PAX3. Mol Cell Biol 1995, 15(3):1522-1535.
3. Newton W.A., Soule E.H., Hamoudi A.B., et al. Histopathology of childhood sarcomas, Intergroup Rhabdomyosarcoma Studies I and II: clinicopathologic correlation. J Clin Oncol 1988, 6(1):67-75.
4. Crist W.M., Garnsey L., Beltangady M.S., et al. Prognosis in children with rhabdomyosarcoma: a report of the Intergroup Rhabdomyosarcoma Studies I and II. Intergroup Rhabdomyosarcoma Committee. J Clin Oncol 1990, 8(3):443-452.
5. Rodeberg D.A., Stoner J.A., Hayes-Jordan A., et al. Prognostic significance of tumor response at the end of therapy in group III rhabdomyosarcoma: a report from the Children's Oncology Group. J Clin Oncol 2009, 27(22):3705-3711.
6. Arndt C.A., Stoner J.A., Hawkins D.S., et al. Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: Children's Oncology Group study D9803. J Clin Oncol 2009, 27(31):5182-5188.
7. Crist W., Gehan E.A., Ragab A.H., et al. The third Intergroup Rhabdomyosarcoma Study. J Clin Oncol 1995, 13(3):610-630.
8. Raney R.B., Maurer H.M., Anderson J.R., et al. The Intergroup Rhabdomyosarcoma Study Group (IRSG): Major lessons from the IRS-I through IRS-IV studies as background for the current IRS-V treatment protocols. Sarcoma 2001, 5(1):9-15.
9. Wolden S.L., Anderson J.R., Crist W.M., et al. Indications for radiotherapy and chemotherapy after complete resection in rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Studies I to III. J Clin Oncol 1999, 17(11):3468-3475.
10. Raney R.B., Anderson J.R., Brown K.L., et al. Treatment results for patients with localized, completely resected (group I) alveolar rhabdomyosarcoma on Intergroup Rhabdomyosarcoma Study Group (IRSG) protocols III and IV, 1984-1997: a report from the Children's Oncology Group. Pediatr Blood Cancer 2010, 55(4):612-616.
11. Breneman J., Meza J., Donaldson S.S., et al. Local control with reduced-dose radiotherapy for low-risk rhabdomyosarcoma: a report from the Children's Oncology Group D9602 study. Int J Radiat Oncol Biol Phys 2012, 83(2):720-726.
12. Raney R.B., Walterhouse D.O., Meza J.L., et al. Results of the Intergroup Rhabdomyosarcoma Study Group D9602 protocol, using vincristine and dactinomycin with or without cyclophosphamide and radiation therapy, for newly diagnosed patients with low-risk embryonal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. J Clin Oncol 2011, 29(10):1312-1318.
13. Million L., Anderson J., Breneman J., et al. Influence of noncompliance with radiation therapy protocol guidelines and operative bed recurrences for children with rhabdomyosarcoma and microscopic residual disease: a report from the Children's Oncology Group. Int J Radiat Oncol Biol Phys 2011, 80(2):333-338.
14. Donaldson S.S., Meza J., Breneman J.C., et al. Results from the IRS-IV randomized trial of hyperfractionated radiotherapy in children with rhabdomyosarcoma - a report from the IRSG. Int J Radiat Oncol Biol Phys 2001, 51(3):718-728.
15. Munter M.W., Karger C.P., Hoffner S.G., et al. Evaluation of salivary gland function after treatment of head-and-neck tumors with intensity-modulated radiotherapy by quantitative pertechnetate scintigraphy. Int J Radiat Oncol Biol Phys 2004, 58(1):175-184.
16. Wolden S.L., Wexler L.H., Kraus D.H., Laquaglia M.P., Lis E., Meyers P.A. Intensity-modulated radiotherapy for head-and-neck rhabdomyosarcoma. Int J Radiat Oncol Biol Phys 2005, 61(5):1432-1438.
17. Lin C., Donaldson S.S., Meza J.L., et al. Effect of radiotherapy techniques (IMRT vs. 3D-CRT) on outcome in patients with intermediate-risk rhabdomyosarcoma enrolled in COG D9803 - a report from the Children's Oncology Group. Int J Radiat Oncol Biol Phys 2012, 82(5):1764-1770.
18. Lomax A.J., Bortfeld T., Goitein G., et al. A treatment planning inter-comparison of proton and intensity modulated photon radiotherapy. Radiother Oncol 1999, 51(3):257-271.
19. Miralbell R., Lomax A., Cella L., Schneider U. Potential reduction of the incidence of radiation-induced second cancers by using proton beams in the treatment of pediatric tumors. Int J Radiat Oncol Biol Phys 2002, 54(3):824-829.
20. Childs S.K., Kozak K.R., Friedmann A.M., et al. Proton radiotherapy for parameningeal rhabdomyosarcoma: clinical outcomes and late effects. Int J Radiat Oncol Biol Phys 2012, 82(2):635-642.
21. Cotter S.E., Herrup D.A., Friedmann A., et al. Proton radiotherapy for pediatric bladder/prostate rhabdomyosarcoma: clinical outcomes and dosimetry compared to intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys 2011, 81(5):1367-1373.
22. Kozak K.R., Adams J., Krejcarek S.J., Tarbell N.J., Yock T.I. A dosimetric comparison of proton and intensity-modulated photon radiotherapy for pediatric parameningeal rhabdomyosarcomas. Int J Radiat Oncol Biol Phys 2009, 74(1):179-186.
23. Yock T., Schneider R., Friedmann A., Adams J., Fullerton B., Tarbell N. Proton radiotherapy for orbital rhabdomyosarcoma: clinical outcome and a dosimetric comparison with photons. Int J Radiat Oncol Biol Phys 2005, 63(4):1161-1168.
24. Wharam M., Beltangady M., Hays D., et al. Localized orbital rhabdomyosarcoma. An interim report of the Intergroup Rhabdomyosarcoma Study Committee. Ophthalmology 1987, 94(3):251-254.
25. Lawrence W., Hays D.M., Heyn R., et al. Lymphatic metastases with childhood rhabdomyosarcoma. A report from the Intergroup Rhabdomyosarcoma Study. Cancer 1987, 60(4):910-915.
26. Stevens M.C., Rey A., Bouvet N., et al. Treatment of nonmetastatic rhabdomyosarcoma in childhood and adolescence: Third study of the International Society of Paediatric Oncology - SIOP Malignant Mesenchymal Tumor 89. J Clin Oncol 2005, 23(12):2618-2628.
27. Wharam M.D., Beltangady M.S., Heyn R.M., et al. Pediatric orofacial and laryngopharyngeal rhabdomyosarcoma. An Intergroup Rhabdomyosarcoma Study report. Arch Otolaryngol Head Neck Surg 1987, 113(11):1225-1227.
28. Simon J.H., Paulino A.C., Smith R.B., Buatti J.M. Prognostic factors in head and neck rhabdomyosarcoma. Head Neck 2002, 24(5):468-473.
29. Curtis A.E., Okcu M.F., Chintagumpala M., Teh B.S., Paulino A.C. Local control after intensity-modulated radiotherapy for head-and-neck rhabdomyosarcoma. Int J Radiat Oncol Biol Phys 2009, 73(1):173-177.
30. McDonald M.W., Esiashvili N., George B.A., et al. Intensity-modulated radiotherapy with use of cone-down boost for pediatric head-and-neck rhabdomyosarcoma. Int J Radiat Oncol Biol Phys 2008, 72(3):884-891.
31. Spunt S.L., Lobe T.E., Pappo A.S., et al. Aggressive surgery is unwarranted for biliary tract rhabdomyosarcoma. J Pediatr Surg 2000, 35(2):309-316.
32. Arndt C.A., Donaldson S.S., Anderson J.R., et al. What constitutes optimal therapy for patients with rhabdomyosarcoma of the female genital tract?. Cancer 2001, 91(12):2454-2468.
33. Martelli H., Oberlin O., Rey A., et al. Conservative treatment for girls with nonmetastatic rhabdomyosarcoma of the genital tract: a report from the Study Committee of the International Society of Pediatric Oncology. J Clin Oncol 1999, 17(7):2117-2122.
34. Magne N., Oberlin O., Martelli H., Gerbaulet A., Chassagne D., Haie-Meder C. Vulval and vaginal rhabdomyosarcoma in children: update and reappraisal of Institut Gustave Roussy brachytherapy experience. Int J Radiat Oncol Biol Phys 2008, 72(3):878-883.
35. Walterhouse D.O., Meza J.L., Breneman J.C., et al. Local control and outcome in children with localized vaginal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. Pediatr Blood Cancer 2011, 57(1):76-83.
36. Wiener E.S., Anderson J.R., Ojimba J.I., et al. Controversies in the management of paratesticular rhabdomyosarcoma: is staging retroperitoneal lymph node dissection necessary for adolescents with resected paratesticular rhabdomyosarcoma?. Semin Pediatr Surg 2001, 10(3):146-152.
37. Benk V., Rodary C., Donaldson S.S., et al. Parameningeal rhabdomyosarcoma: results of an international workshop. Int J Radiat Oncol Biol Phys 1996, 36(3):533-540.
38. Michalski J.M., Meza J., Breneman J.C., et al. Influence of radiation therapy parameters on outcome in children treated with radiation therapy for localized parameningeal rhabdomyosarcoma in Intergroup Rhabdomyosarcoma Study Group trials II through IV. Int J Radiat Oncol Biol Phys 2004, 59(4):1027-1038.
39. St Clair W.H., Adams J.A., Bues M., et al. Advantage of protons compared to conventional X-ray or IMRT in the treatment of a pediatric patient with medulloblastoma. Int J Radiat Oncol Biol Phys 2004, 58(3):727-734.
40. Neville H.L., Andrassy R.J., Lobe T.E., et al. Preoperative staging, prognostic factors, and outcome for extremity rhabdomyosarcoma: a preliminary report from the Intergroup Rhabdomyosarcoma Study IV (1991-1997). J Pediatr Surg 2000, 35(2):317-321.
41. La T.H., Wolden S.L., Su Z., et al. Local therapy for rhabdomyosarcoma of the hands and feet: is amputation necessary? A report from the Children's Oncology Group. Int J Radiat Oncol Biol Phys 2011, 80(1):206-212.
42. Paulino A.C., Pappo A. Alveolar rhabdomyosarcoma of the extremity and nodal metastasis: is the in-transit lymphatic system at risk?. Pediatr Blood Cancer 2009, 53(7):1332-1333.
43. La T.H., Wolden S.L., Rodeberg D.A., et al. Regional nodal involvement and patterns of spread along in-transit pathways in children with rhabdomyosarcoma of the extremity: a report from the Children's Oncology Group. Int J Radiat Oncol Biol Phys 2011, 80(4):1151-1157.
44. Chui C.H., Billups C.A., Pappo A.S., Rao B.N., Spunt S.L. Predictors of outcome in children and adolescents with rhabdomyosarcoma of the trunk - the St Jude Children's Research Hospital experience. J Pediatr Surg 2005, 40(11):1691-1695.
45. Blakely M.L., Lobe T.E., Anderson J.R., et al. Does debulking improve survival rate in advanced-stage retroperitoneal embryonal rhabdomyosarcoma?. J Pediatr Surg 1999, 34(5):736-741. discussion 741-742.
46. Raney R.B., Stoner J.A., Walterhouse D.O., et al. Results of treatment of fifty-six patients with localized retroperitoneal and pelvic rhabdomyosarcoma: A report from the Intergroup Rhabdomyosarcoma Study-IV, 1991-1997. Pediatr Blood Cancer 2004, 42(7):618-625.
47. Hays D.M., Raney R.B., Wharam M.D., et al. Children with vesical rhabdomyosarcoma (RMS) treated by partial cystectomy with neoadjuvant or adjuvant chemotherapy, with or without radiotherapy. A report from the Intergroup Rhabdomyosarcoma Study (IRS) Committee. J Pediatr Hematol Oncol 1995, 17(1):46-52.
48. Hays D.M., Lawrence W., Crist W.M., et al. Partial cystectomy in the management of rhabdomyosarcoma of the bladder: a report from the Intergroup Rhabdomyosarcoma Study. J Pediatr Surg 1990, 25(7):719-723.
49. Arndt C., Rodeberg D., Breitfeld P.P., Raney R.B., Ullrich F., Donaldson S. Does bladder preservation (as a surgical principle) lead to retaining bladder function in bladder/prostate rhabdomyosarcoma? Results from Intergroup Rhabdomyosarcoma Study IV. J Urol 2004, 171(6 Pt 1):2396-2403.